ENTRADA THERAPEUTICS INC. - COMMON STOCK

Entrada Therapeutics Reports Second Quarter 2022 Financial Results

11 авг 2022 04:00:02 Источник Nasdaq GlobeNewswire

Entrada Therapeutics Announces Collaboration with the Myotonic Dystrophy Clinical Research Network to Study the Natural History of Myotonic Dystrophy Type 1

04 авг 2022 04:00:03 Источник Nasdaq GlobeNewswire

Entrada Therapeutics Appoints Karla MacDonald as Chief Corporate Affairs Officer

19 июл 2022 04:00:00 Источник Nasdaq GlobeNewswire

Entrada Therapeutics to Present at William Blair Biotech Focus Conference

06 июл 2022 04:00:00 Источник Nasdaq GlobeNewswire

Entrada Therapeutics to Present at Goldman Sachs Global Healthcare Conference

01 июн 2022 04:00:02 Источник Nasdaq GlobeNewswire

Entrada Therapeutics Reports First Quarter 2022 Financial Results

12 май 2022 04:00:01 Источник Nasdaq GlobeNewswire

Entrada Therapeutics Presents New Data Supporting its Growing Pipeline of Endosomal Escape Vehicle (EEV™) Therapeutics at TIDES USA 2022

11 май 2022 06:30:00 Источник Nasdaq GlobeNewswire

Entrada Therapeutics to Present at H.C. Wainwright Global Investment Conference

10 май 2022 04:00:03 Источник Nasdaq GlobeNewswire

Entrada Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

15 мар 2022 04:00:01 Источник Nasdaq GlobeNewswire

Entrada Therapeutics to Participate in Cowen 42nd Annual Health Care Conference

23 фев 2022 05:00:02 Источник Nasdaq GlobeNewswire

Entrada Therapeutics Announces the Appointment of Jared Cohen, PhD, JD to General Counsel

05 янв 2022 05:00:03 Источник Nasdaq GlobeNewswire

Entrada Therapeutics to be Added to Russell 2000® and Russell 3000® Indexes

17 дек 2021 05:00:00 Источник Nasdaq GlobeNewswire

Entrada Therapeutics Reports Third Quarter 2021 Financial Results

09 дек 2021 04:00:00 Источник Nasdaq GlobeNewswire